ABBV
More long-term ammo for AbbVie
AbbVie showed off fresh nine-year data for its venetoclax-based combo at the European Hematology Association 2026 Congress, and the headline is basically: this thing still works. In the Phase 3 CLL14 trial, venetoclax plus obinutuzumab beat chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients with coexisting medical conditions.
Why investors should care
This isn’t just academic confetti. The final analysis showed a median progression-free survival of 6.4 years for the venetoclax combo versus 3.2 years for the older regimen, and the median time to next treatment stretched to 7.6 years. Translation: patients stayed off the treatment treadmill longer, which is exactly the sort of durability that helps a drug stay commercially relevant.
The stock-market angle
AbbVie shares nudged higher on the news, which makes sense. When a company keeps finding new ways to remind the market that an old drug still has legs, that’s franchise defense 101. And in pharma, “durable efficacy” is investor code for “maybe we don’t have to panic about the revenue cliff today.”
The bigger picture
AbbVie has been leaning hard on the idea that its pipeline and core brands can keep the engine humming, and this update fits neatly into that story. Big picture: in biotech, the best drug is often the one that refuses to look dated.